• Most Popular
  • Most Shared

Teva gets FDA nod to market generic version of Abbott antibiotic

Thu May 10, 2007 10:00am EDT

Stocks

   

May 10 (Reuters) - Teva Pharmaceutical Industries Ltd. (TEVA.O) said it has received regulatory approval to sell a generic version of Abbott Laboratories Inc.'s (ABT.N) antibiotic Omnicef in both capsule and oral suspension forms.

Omnicef capsules and Omnicef oral suspension had annual sales of about $325 million and $533 million, respectively, in the United States, according to IMS sales data.

Israel-based Teva is currently involved in a patent litigation with Abbott over this product.

(Reporting by Dhanya Skariachan in Bangalore)

((Editing by Rumman Ahmed; Reuters messaging: dhanya.skariachan.reuters.com@reuters.net; within U.S. +1 646 223 8780; outside U.S. +91 80 4135 5800)) Keywords: TEVA PATENT/

(C) Reuters 2007. All rights reserved. Republication or redistribution ofReuters content, including by caching, framing or similar means, is expresslyprohibited without the prior written consent of Reuters. Reuters and the Reuterssphere logo are registered trademarks and trademarks of the Reuters group ofcompanies around the world.nWNAS1000


More from Reuters

Photo

U.S. probing if al Qaeda linked to airplane incident

WASHINGTON (Reuters) - The Obama administration said on Sunday it was investigating whether al Qaeda was involved in a Christmas Day attempt to blow up a passenger jet and sought to head off Republican attacks over its anti-terrorism measures. | Video

» More Top News
A Delta Airbus 330 airliner sits on a runway at Detroit Metropolitan Airport in Romulus, Michigan in this video grab made December 25, 2009. Credit: REUTERS/WDIV TV/Handout

The battle in mid-air

The attraction of bombing airliners means the aviation industry has to be constantly vigilant in its fight against attackers.  Full Article 

U.S.
A caution sign is seen next to a stock board at the Australian Securities Exchange (ASX) in Sydney September 5, 2008. REUTERS/Daniel Munoz
Political Risk in 2010:

Don't say we didn't warn you

With the financial crisis (mostly) in the past, U.S. investors are eying a fresh start to the coming year. Here's a look at what speedbumps lie ahead.  Full Article 

Global Markets